Taste dysfunction rises steeply at lower tongue mucosal doses during head and neck IMRT
In 32 head and neck cancer patients, taste dysfunction increased nonlinearly with cumulative tongue mucosal dose, without a validated 20-Gy threshold.
In 32 head and neck cancer patients, taste dysfunction increased nonlinearly with cumulative tongue mucosal dose, without a validated 20-Gy threshold.
Across 1,442 head and neck cancer patients, Bayesian ridge achieved the best imputation accuracy, while advanced methods showed similar downstream NTCP performance.
Across 137 studies, specific cardiac substructures repeatedly showed dose–toxicity relationships, while evidence linking radiation-induced cardiac injury directly to survival remained limited.
One-third of patients developed malnutrition during nasopharyngeal RT, while prophylactic enteral nutrition was associated with better post-treatment weight stabilization.
After head and neck RT, 43% of patients lost teeth and higher oral cavity dose was associated with tooth loss.
In a small ESTRO poll, subjective and lower-grade adverse events showed substantial disagreement despite shared CTCAE v6.0 definitions.
Two prostate RT cases suggest that focal lumbosacral plexus hotspots, particularly near 70 Gy, may contribute to severe neurologic toxicity.
Treatment discontinuation was 25.0% with pre-RT cachexia versus 4.6% without, with approximately sixfold higher adjusted odds.
HYPO-RT-PC showed persistently poor agreement between patient- and clinician-reported toxicity, particularly for urinary and bowel symptoms.
Compared with 8 Gy in one fraction, five- and ten-fraction regimens were associated with approximately two- and threefold higher odds of lymphopenia.
Random forest reached external AUC 0.769 for 12-month radiation-induced hypothyroidism, but calibration and clinical utility weakened outside the development center.
Unplanned radiotherapy interruptions occurred in 35% and were associated with lower response, more toxicity and markedly worse six-month survival.
Severe lymphopenia occurred in 44%, while baseline and week-2 lymphocyte counts outperformed 600 dosimetric variables for risk prediction.
Ninety-five percent completed 55 Gy in 20 fractions, with encouraging outcomes in early p16-positive oropharyngeal cancer despite substantial acute toxicity.
FLASH protons largely preserved ocular structure and retinal function after 24 Gy while maintaining short-term tumor control in mice.